Literature DB >> 26743481

Pulmonary hypertension associated with ponatinib therapy.

Fleur-Marie Quilot1, Marjolaine Georges1, Nicolas Favrolt2, Guillaume Beltramo1, Clément Foignot1, Aurélie Grandvuillemin3, David Montani4, Philippe Bonniaud5, Philippe Camus6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26743481     DOI： 10.1183/13993003.01110-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  13 in total

1.  Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension.

Authors:  Marie-Camille Chaumais; Caroline O'Connell; Laurent Savale; Christophe Guignabert; Frédéric Perros; Xavier Jaïs; Olivier Sitbon; Marc Humbert; David Montani
Journal:  Int J Clin Pharm       Date:  2018-08-13

2.  Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension.

Authors:  Takumi Toya; Yuji Nagatomo; Kazuki Kagami; Midori Yukino; Risako Yasuda; Takayuki Namba; Yasuo Ido; Shinichi Kobayashi; Nobuyuki Masaki; Hirotaka Yada; Fumihiko Kimura; Takeshi Adachi
Journal:  Int J Cardiovasc Imaging       Date:  2019-02-04       Impact factor: 2.357

Review 3.  Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib.

Authors:  Grazia Casavecchia; Maurizio Galderisi; Giuseppina Novo; Matteo Gravina; Ciro Santoro; Eustachio Agricola; Silvana Capalbo; Stefano Zicchino; Matteo Cameli; Luisa De Gennaro; Francesca Maria Righini; Ines Monte; Carlo Gabriele Tocchetti; Natale Daniele Brunetti; Cristian Cadeddu; Giuseppe Mercuro
Journal:  Heart Fail Rev       Date:  2020-05       Impact factor: 4.214

4.  Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Authors:  Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-08       Impact factor: 5.464

Review 5.  Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.

Authors:  Chelsea C Estrada; Alejandro Maldonado; Sandeep K Mallipattu
Journal:  J Am Soc Nephrol       Date:  2019-01-14       Impact factor: 10.121

Review 6.  Dasatinib-induced pulmonary arterial hypertension.

Authors:  Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

7.  iPSC-endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension.

Authors:  Mingxia Gu; Michele Donato; Minzhe Guo; Neil Wary; Yifei Miao; Shuai Mao; Toshie Saito; Shoichiro Otsuki; Lingli Wang; Rebecca L Harper; Silin Sa; Purvesh Khatri; Marlene Rabinovitch
Journal:  Sci Transl Med       Date:  2021-05-05       Impact factor: 17.956

8.  Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation.

Authors:  Jesus Paez-Mayorga; Andrew L Chen; Sivareddy Kotla; Yunting Tao; Rei J Abe; Emma D He; Brian P Danysh; Marie-Claude C Hofmann; Nhat-Tu Le
Journal:  Front Cardiovasc Med       Date:  2018-09-06

Review 9.  A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.

Authors:  Zahra Nekoukar; Minoo Moghimi; Ebrahim Salehifar
Journal:  Blood Res       Date:  2021-12-31

Review 10.  Repurposing of Kinase Inhibitors for Treatment of COVID-19.

Authors:  Ellen Weisberg; Alexander Parent; Priscilla L Yang; Martin Sattler; Qingsong Liu; Qingwang Liu; Jinhua Wang; Chengcheng Meng; Sara J Buhrlage; Nathanael Gray; James D Griffin
Journal:  Pharm Res       Date:  2020-08-10       Impact factor: 4.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.